Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

They’ve been heralded as the magic drugs that treat obesity when diet and exercise have failed. But Ozempic and Wegovy – and ...

Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 512.66% and ...

Data continue to show that tirzepatide, called Mounjaro for type 2 diabetes and Zepbound for weight loss, is safe and effective, but side effects remain.

Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...

Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing ...

GP leaders have warned that the rollout of the weight loss drug tirzepatide (Mounjaro, Eli Lilly) will still have ...

Meds like Wegovy are all over the news. But are they right for you, especially if you’re older than the average user?

US: Sharing the topline results from the SURMOUNT-5 phase 3b open-label randomized clinical trial, Eli Lilly and Company ...

Tirzepatide had received approval in a single-dose prefilled pen format in January 2024 for use as an adjunct to diet and ...